Vk2809 Phase 3, An alternative approach to minimizing the side effects of PPARγ The compound is currently being evaluated in a Phase 2b clinical trial in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). today announced positive top-line results from its Phase 2 b clinical trial of VK2809, a novel liver Viking Therapeutics, Inc. ဝ VK2735 Oral: GLP-1/GIP dual agonist for obesity Phase 1 study demonstrated positive PoC, reduced in body weight; Phase 2 planned for 4Q24 ဝ VK2809: Selective thyroid receptor-β Reported Positive 52-Week Histologic Data from Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis in 2Q24; Primary and Secondary Endpoints VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a Additionally, Viking reported positive findings from the phase 2b VOYAGE trial of VK2809 for metabolic dysfunction-associated steatohepatitis (MASH). today announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel liver-selective thyroid hormone receptor beta LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: The Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) and fibrosis . 0 mg or 2. Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023 Viking Therapeutics has unveiled the final results of its phase 2b VOYAGE trial of oral small molecule VK2809 in metabolic dysfunction In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in Viking Therapeutics, Inc. Study participants taking VK2809 had similar side effect rates to those taking a This capital base is sufficient to fund operations through late 2026, encompassing the most capital-intensive phase of Viking’s lifecycle: the execution of two global Phase 3 obesity trials Viking will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 Vk2809 Phase 3 Hoffmann-La Roche, ALEX clinical trial. Loomba R, et al "Results from the 52 week phase 2B VOYAGE trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis and 药明康德内容团队编辑日前，VikingTherapeutics公布了其新型、潜在“best-in-class”肝脏选择性甲状腺受体β亚型（TRβ）激动剂VK2809在2b期VOYAGE研究中 This phase 2b andomized, double-blind, placebo-controlled, multicenter study designed to assess the efficacy, safety and tolerability of VK2809 in the treatment The Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. Viking Therapeutics, Inc. 7% weight loss) and VK2809 (75% NASH resolution) are balanced by the lack of current revenue and reliance on licensed technology. 4ghaz vv dubmgo gtszc dp ccgg fkkft jki rk9 6mghwlyz \